Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

88 results about "GDF15" patented technology

Growth/differentiation factor 15 (GDF15) was first identified as Macrophage inhibitory cytokine-1 or MIC-1. It is a protein belonging to the transforming growth factor beta superfamily. Under normal conditions, GDF-15 is expressed in low concentrations in most organs and upregulated because of injury of organs such as such as liver, kidney, heart and lung.

CMyBPC marker combination for early discrimination of acute myocardial infarction type 2 and type 1

PendingCN118922721AMedical automated diagnosisDisease diagnosisESM1Lipid biomarker
The present invention relates to a method for assessing myocardial infarction, the method comprising the steps of: determining the amount of a first biomarker in a sample of a subject, the first biomarker being cMyBPC; determining an amount of a second biomarker in a sample of the subject, wherein the second biomarker is selected from the group consisting of BMP10 type peptide (bone morphogenetic protein type 10 peptide), FGF23 (fibroblast growth factor 23), BNP type peptide (brain natriuretic peptide type peptide), GDF-15 (growth differentiation factor 15), ANG2 (angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1) or such as cholesterol, LDL (low density lipoprotein) or APOAT (apolipoprotein A-1) a lipid biomarker; comparing the amount of biomarker to a reference for the biomarker and / or calculating a score for assessing myocardial infarction based on the amount of biomarker; and assessing the subject based on the comparison and / or calculation. The invention also relates to the use of a first biomarker, which is cMyBPC, and a second biomarker, which is selected from the group consisting of a BMP10 type peptide, FGF23, a BNP type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1 or a lipid biomarker such as cholesterol or LDL, for assessing myocardial infarction; or at least one detection agent for the first biomarker and at least one detection agent for the second biomarker. In addition, the invention further relates to a computer-implemented method for assessing myocardial infarction as well as a device and a kit for assessing myocardial infarction.
Owner:F HOFFMANN LA ROCHE & CO AG

Antibody molecule against growth and differentiation factor 15 and use thereof

Provided in the present disclosure is an antibody or fragment thereof against a human growth and differentiation factor 15 (GDF15). Further provided in the present disclosure is the use of the antibody or fragment thereof in the preparation of a drug for treating diseases or conditions. The antibody or fragment thereof provided in the present disclosure can bind to human GDF15 with high affinity and specificity, blocks the interaction of GDF15 with receptor GFRAL thereof, and has a longer half-life period in vivo in comparison with antibodies of the same kind.
Owner:YUNNAN BAIYAO GRP CO LTD

Application of reagent for detecting GDF15 protein in preparation of product for evaluating myocardial infarction risk of subject in future

The invention provides application of a reagent for detecting GDF15 protein in preparation of a product for evaluating the myocardial infarction risk of a subject in the future, and belongs to the technical field of biomedical detection. By detecting the concentration level of the GDF15 protein in peripheral blood, the risk of myocardial infarction of a subject in the future can be accurately predicted in the early stage, so that early risk guidance is provided for crowds needing intervention, and the application is non-invasive, simple, convenient and low in cost. In order to achieve the maximum economic benefit, only the GDF15 level in the peripheral trace blood of the subject needs to be detected, the clinical index level needed in a traditional model is not needed, the prediction level of a traditional method is exceeded, and meanwhile the economic cost is greatly reduced.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Human recombinant GDF15 protein and application thereof in preparation of medicine for preventing and treating sepsis acute kidney injury

The invention relates to a human recombinant GDF15 protein and application thereof in preparation of drugs for preventing and treating sepsis acute kidney injury, and belongs to the technical field of biological medicines. In order to solve the problem that an effective prevention and treatment scheme for improving SA-AKI by inhibiting oxygen death is lacked in existing clinical and research, the invention provides a human recombinant GDF15 protein of which the coding gene nucleotide sequence is shown as SEQ ID No: 1. Animal experiment results show that by intraperitoneal injection of the human recombinant GDF15 protein, kidney inflammation of sepsis mice can be relieved, and expression of PGAM5 can be down-regulated. Cell experiment results show that when the human recombinant GDF15 protein is given, LPS-induced USF2 increase can be inhibited. The human recombinant GDF15 protein provided by the invention can improve SA-AKI by inhibiting oxygen death and inflammation, provides a new idea and an intervention target for prevention and treatment of SA-AKI, and shows a good clinical application prospect.
Owner:HARBIN MEDICAL UNIVERSITY

Application of fatty acid oxidation inhibitor in improving cis-platinum resistance of esophageal squamous carcinoma

The invention discloses an application of a fatty acid oxidation inhibitor in improving cis-platinum resistance of esophageal squamous carcinoma, and particularly relates to the technical field of biology. The invention discloses application of a fatty acid oxidation inhibitor in preparation of a product for improving cisplatin resistance of esophageal squamous carcinoma. The fatty acid oxidation inhibitor is etomox. The invention discloses a very good effect of the fatty acid beta oxidation inhibitor Etomoxir on weakening the cisplatin resistance of esophageal squamous carcinoma cells induced by M2 type macrophage-derived GDF15 for the first time. According to the invention, the fatty acid beta oxidation inhibitor Etomoxir is combined with cis-platinum to be applied to the treatment process of esophageal cancer, so that the esophageal cancer chemotherapy drug resistance process mediated by tumor-associated macrophages is effectively weakened.
Owner:SHIHEZI UNIVERSITY

Anti-gfral antibody and application thereof

An anti-GFRAL antibody and a use thereof. The anti-GFRAL antibody or an antigen-binding portion thereof can be used for treating or preventing GFRAL-mediated or GFRAL-RET-GDF15 signaling pathway-mediated diseases or abnormalities, particularly cachexia syndrome.
Owner:SHANGHAI JMT BIO TECHNOLOGY CO LTD

Application of GDF15 in preparation of medicine for treating DON poisoning and medicine thereof

PendingCN119386165AInhibit proliferation and differentiationGrowth inhibitionPeptide/protein ingredientsAntinoxious agentsMature erythrocyteReticulocyte count decreased
The invention provides application of GDF15 in preparation of a medicine for treating or preventing hematopoietic dysfunction caused by DON poisoning. The research finds that the GDF15 has the effects of treating or preventing bone marrow total cell reduction, hematopoietic stem progenitor cell damage, erythroid progenitor cell damage, erythroid end developmental stage damage, reticulocyte number reduction and peripheral blood mature erythrocyte damage caused by DON poisoning, and the exogenous GDF15 can relieve inhibition of DON poisoning on cell growth and development through research. And a GDF15-beta-catenin-Myc signal channel is activated, so that the downstream Myc, p27 and p21 are normally expressed. The invention discloses a new application of GDF15 in treatment of DON poisoning.
Owner:ZHENGZHOU UNIV

Application of detection reagent for GDF15 in extracellular vesicles in preparation of prostate cancer diagnosis and / or staging kit

PendingCN120254267ADisease diagnosisBiological testingClinical cohortOncology
The invention belongs to the technical field of in-vitro diagnostic reagents, and particularly relates to application of a detection reagent for GDF15 protein in extracellular vesicles in preparation of a prostate cancer diagnosis and / or staging kit. According to the invention, enrichment and proteomics detection are carried out on plasma EVs of patients with prostatic cancer (PCa) and benign prostatic hyperplasia (BPH), and through bioinformatics analysis, a potential EV protein marker GDF15 which can be used for early diagnosis of PCa is screened for the first time. The GDF15 protein is verified in a plurality of groups of new clinical queues by further adopting an immunological technology and a targeted quantitative mass spectrometry technology, and the distinguishing ability of the GDF15 protein to PCa and BPH and the distinguishing ability of the GDF15 protein to different PCa stages are determined. The method is expected to promote noninvasive precise diagnosis of clinical PCa, and has a good application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Application of GDF15 inhibitor targeting TCF19 in preparation of medicine for treating liver cancer

PendingCN118987221AReduce the difficulty of manufacturing technologyDigestive systemMicrobiological testing/measurementMonoclonal antibodyPharmaceutical drug
The invention aims to provide application of a GDF15 inhibitor targeting TCF19 in preparation of a medicine for treating liver cancer. Compared with an existing GDF15 antagonist, the GDF15 antagonist has the advantages that (1) it is found for the first time that TCF19 directly inhibits expression of GDF15 from the transcriptional level instead of the protein level; and (2) compared with direct preparation of the GDF15 neutralizing monoclonal antibody, an upstream regulatory factor is provided as a target inhibitor, the preparation technical difficulty is lower, and the GDF15 neutralizing monoclonal antibody has a wide application prospect.
Owner:HANGZHOU NORMAL UNIVERSITY

Mr-proadm marker panels for early detection of sepsis

The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being MR-proADM, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFlt-1, GDF15 and ESM1, comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being MR-proADM and a second biomarker selected from the group consisting of: sFlt-1, GDF15 and ESM1, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC

Glioma targeting nanocapsule containing Cas9 / sgGDF15 compound as well as preparation method and application of glioma targeting nanocapsule

The invention discloses a nanocapsule for targeting glioma containing a Cas9 / sgGDF15 compound as well as a preparation method and application of the nanocapsule, and belongs to the technical field of biological medicines. According to the nanocapsule disclosed by the invention, the glioma targeting peptide Ang with strong brain penetrating power is cross-linked on the surface, so that the glioma targeting property of the nanocapsule is improved; a disulfide bond is added on the surface of the nanocapsule, so that the nanocapsule can be prevented from being degraded by enzyme action in blood, and a Cas9 / sgGDF15 compound entrapped in the nanocapsule can be ruptured and accurately released in a high glutathione microenvironment at a tumor part of the nanocapsule, so that the GDF15 gene of glioma cells is efficiently edited, and the GDF15 gene in the glioma cells is specifically knocked out; the immunosuppressive microenvironment of the glioma is reversed, the anti-tumor effect of immune cells is recovered, and the aim of treating the glioma is achieved.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Universal AKI, CKD and AKI-CKD progress prediction model based on plasma proteomics and construction method thereof

The invention discloses an AKI, CKD and AKI-CKD progress general prediction model based on plasma proteomics and a construction method thereof. The construction method comprises the following steps: selecting a patient which has plasma proteomics data when a baseline which meets the inclusion standard of a research group, has eGFR greater than or equal to 60mL / min / 1.73 m < 2 > when the baseline exists, and has no AKI or CKD medical history; collecting clinical prediction factors and blood proteomics data of the modeling crowd; and randomly dividing the selected modeling crowd data into a training set and a verification set, screening out protein prediction markers such as protein WFDC2 and protein GDF15 shared with the development of the AKI, the CKD and the AKI-CKD, and establishing a general prediction model for the development of the AKI, the CKD and the AKI-CKD. Proteomics is used for predicting AKI-CKD progress for the first time, three renal function outcomes can be predicted at the same time, prediction indexes are simple and easy to obtain, and the model is a universal model with high prediction capacity.
Owner:GUANGDONG GENERAL HOSPITAL

Compositions targeting au-rich elements of FGF21 gene and GDF15 gene and methods of use thereof

This disclosure generally relates to methods and compositions for functional genetic modifications at selected genomic sites, such as the FGF21 gene or the GDF15 gene. This disclosure further provides compositions and methods for genomic editing of AU-rich elements in the FGF21 and / or GDF15 genes for treating obesity-related diseases and disorders.
Owner:POSEIDA THERAPEUTICS INC

Methods for treating pulmonary disease with a ligand binding domain of a TGF-β type II receptor

ActiveUS12678483B2DiseaseRight ventricular hypertrophy
In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.
Owner:ACCELERON PHARMA INC +1

CKD early screening marker based on plasma proteomics and application

PendingCN120685912ADisease diagnosisBiological testingPlasma proteomicsOncology
The invention provides a CKD early screening marker based on plasma proteomics. The early screening marker comprises the following five kinds of protein: IGFBP4, GDF15, EDA2R, HAVCR1 and XG. The early screening marker provided by the invention can provide ultra-early warning within 16 years before disease attack, is high in prediction accuracy, and is superior to the conventional model in short-term and long-term prediction aspects; meanwhile, a key proteome pathway is disclosed, and reference can be provided for clinical application and prevention strategies. The invention also provides application of the early screening marker based on the CKD.
Owner:GUANGDONG GENERAL HOSPITAL

Compositions and methods for treating pulmonary hypertension

In some aspects, the invention teaches pharmaceutical compositions comprising a TGF-beta ligand trapping agent, and methods of using the TGF-beta ligand trapping agent to treat, prevent, or reduce the rate of progression of pulmonary hypertension (PH). The invention also provides methods of using the TGF-beta ligand trapping agents to treat, prevent, or reduce the rate of progression of a variety of disorders, the conditions include, but are not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using the TGF-beta ligand trapping agent to reduce right ventricular systolic pressure in a subject.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1

Antibodies against gdf15 and methods and uses thereof

PendingCN122349531AGDF15Antibody
A GDF15 binding molecule, in particular an antibody and fragments thereof that specifically recognize GDF15. Nucleic acids or host cells comprising such antibodies or fragments thereof, medicaments comprising such antibodies or fragments thereof, and therapeutic and diagnostic methods or uses applying these antibodies and fragments.
Owner:NANJING LEADS BIOLABS CO LTD

Methods of preventing or treating diseases, conditions, or disorders associated with chemotherapy

In certain embodiments, provided herein are compositions, kits, methods and uses that are useful for preventing or treating a subject suffering from one or more diseases, conditions or disorders associated with chemotherapy such as anthracycline treatment. In some embodiments, provided is a method of treating or preventing a disease, condition or disorder resulting from or exacerbated by chemotherapy treatment in a subject, comprising the step of: administering an effective amount of GDF15 to the subject prior to the chemotherapy. Other example embodiments are described herein. In certain embodiments, the provided novel compositions, kits, methods and uses are highly effective in reducing cardiac cytotoxicity, cheaper, and safer for use.
Owner:THE CHINESE UNIVERSITY OF HONG KONG

Method for estimating the rate of senescent immune cells

The objective is to provide a simple and indirect method for estimating the rate of senescent immune cells (the ratio of immune cells with high SAβgal expression levels among T cells whose surface marker is CD8-positive) using a small amount of blood sample. [Solution] This method estimates the rate of senescent immune cells using the relative expression levels of one or more selected from Granzyme K, α-Klotho, GDF15, PAI-1 (SERPIN1), and ferritin in the blood.
Owner:FUAN KERU

Fatty acids and their use in conjugation to biomolecules

The present invention relates to the following chemical formulas A1, A2, or A3 through a linker The present invention provides a conjugate comprising a biomolecule linked to a fatty acid having [wherein R1, R2, R3, R4, Ak, n, m, and p are defined herein]. The present invention also relates to a method for preparing the conjugate of the present invention, such as a GDF15 conjugate, and the therapeutic use thereof, such as the treatment or prevention of metabolic disorders or diseases, type 2 diabetes, obesity, pancreatitis, dyslipidemia, alcoholic and non-alcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral artery disease, stroke, heart failure, coronary heart disease, complications of diabetes (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of a pharmacologically active agent and a pharmaceutical composition.
Owner:NOVARTIS AG

Anti-GDF15 antibody, and method and use therefor

A GDF15 binding molecule, in particular an antibody specifically recognizing GDF15 and a fragment thereof. A nucleic acid or host cell containing the antibody or fragment thereof, a drug containing the antibody or fragment thereof, and a therapeutic and diagnostic method or use applying the antibody and fragment.
Owner:NANJING LEADS BIOLABS CO LTD

Growth differentiation factor 15 (GDF-15) constructs

To provide constructs comprising GDF15 and mutants thereof.SOLUTION: A fusion protein comprising a GDF15 region and an Fc domain are provided. In various embodiments, constructs comprising GDF15 and mutants thereof can be of use in treating or ameliorating a metabolic disorder. In various embodiments, the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.SELECTED DRAWING: None
Owner:AMGEN INC

GDF-15 nanoantibody and use thereof

The present invention provides a GDF15-binding nanoantibody, and a use thereof in preparation of a drug for treating tumor cachexia and in detection of GDF15. The nanoantibody provided in the present invention exhibits high affinity for GDF-15 and is capable of blocking the binding of GDF-15 to GFRAL.
Owner:LETO LAB CO LTD

GDF15 detection method and kit based on homogeneous light-activated chemiluminescence immunoassay technology

The invention discloses a GDF15 detection method based on a homogeneous-phase light-excited chemiluminescence immunoassay technology and a kit. The detection method comprises the following steps: preparing donor microspheres coupled with a GDF15 capture antibody and receptor microspheres coupled with a GDF15 detection antibody, uniformly mixing and incubating a sample to be detected and the coupled donor microspheres and receptor microspheres, and performing fluorescence detection to obtain the GDF15 concentration of the sample to be detected. The kit comprises donor microspheres coupled with a GDF15 capture antibody, receptor microspheres coupled with a GDF15 detection antibody, a GDF15 standard substance solution and an analysis buffer solution. According to the invention, the carboxyl modified microspheres are used, so that the coupling efficiency with the antibody is higher; the GDF15 content in a to-be-detected sample can be rapidly detected by applying a double-antibody sandwich immunoassay and light-activated chemiluminescence characteristics, the detection range is wide, the sensitivity and the accuracy are high, the detection is rapid, simple and convenient, and the GDF15 detection kit can be clinically used for early auxiliary diagnosis of cardiovascular diseases such as HF and MI and has a good application prospect.
Owner:ZHEJIANG SCI-TECH UNIV

Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof

To provide a GLP1 analogue or derivative thereof and / or a GDF15 analogue or derivative thereof with improved metabolic stability and pharmacokinetic profile relative to GLP1 or GDF15, respectively.SOLUTION: A glucagon-like peptide-1 (GLP1) / growth differentiation factor 15 (GDF15) fusion protein is provided, wherein the GLP1-GDF15 fusion protein comprises a GLP1 peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.SELECTED DRAWING: None
Owner:JANSSEN SCI IRELAND UC

Electrophile-containing catechol-o-methyltransferase (COMT) inhibitors for targeting the KEAP1 / NRF2 pathway

PCT designated stageWO2025162373A1Senses disorderNervous disorderDiseaseAntioxidant Response Elements
Provided herein is a method for treating or preventing a disease or disorder associated with a deregulated NRF2 / KEAP1 pathway, comprising administering a subject in need thereof a therapeutically effective amount of entacapone or nitecapone or a pharmaceutically acceptable salt thereof; and entacapone or nitecapone can reversibly bind to KEAP1, those compounds activated NRF2 in vitro and in vivo by reversibly modifying C151 on KEAP1, and both drugs can enhance the expression of growth differentiation factor 15 (GDF15) and NRF2 downstream antioxidant response elements (ARE) genes.
Owner:NAT INST OF BIOLOGICAL SCI BEIJING

Antagonistic peptides of gdf15 and uses thereof

PendingCN122277661ABiological validationPharmaceutical Substances
This invention belongs to the field of biomedical technology, specifically relating to a GDF15 antagonistic peptide and its application. The amino acid sequence of the antagonistic peptide is shown in SEQ ID NO.1. To improve drug stability and blood-brain barrier penetration, GDF15-A-Pep was fused with albumin and transferrin receptor nanobodies. Biological validation results showed that the fusion protein significantly inhibited GDF15-induced MMP1 transcription and protein expression, and exhibited potent antagonistic activity in reporter gene experiments. This invention not only reveals the key structural basis of GDF15 receptor recognition but also provides experimental evidence for the development of novel GDF15 antagonistic drugs with central regulatory potential.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY